Inhibition of Postmenopausal Osteoporosis in Ovariectomized Mice by Huo Xue Tong Luo Capsule Using Network Pharmacology-based Mechanism Prediction and Pharmacological Validation
Huo Xue Tong Luo Capsule (HXTL) has been clinically used to treat osteonecrosis of the femoral head, osteoporosis, and other bone and joint diseases with promising effects. Our previous study has shown that HXTL can promote osteogenesis in mesenchymal stem cells by inhibiting lncRNA-Miat expression through histone modifications. However, the mechanism by which HXTL treats postmenopausal osteoporosis (PMOP) remains unclear. In this study, we used network pharmacology-based mechanism prediction, molecular docking, and pharmacological validation to investigate the mechanism of HXTL in treating PMOP.
Authors
- Yamei Liu (ORCID: https://orcid.org/0000-0002-0770-8381)
- Fengyuan Che (ORCID: https://orcid.org/0000-0003-1278-5899)
- Liangliang Xu (ORCID: https://orcid.org/0000-0002-5249-7480)
- Qiushi Wei (ORCID: https://orcid.org/0000-0002-1274-9997)
- Qiangqiang Zhao (ORCID: https://orcid.org/0000-0002-1622-7547)
- Hongxiao Li (ORCID: https://orcid.org/0000-0001-8338-6604)
- Ruying Hu
- Liuchao Hu
Publication Details
- Journal
- Future Integrative Medicine
- Published
- 2025-03-25
- DOI
- https://doi.org/10.14218/fim.2024.00049
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Traditional Chinese Medicine Bureau of Guangdong Province